Emily Bodnar Reiterates Buy on AnaptysBio, Keeps $30 Price Target on ANB033 Progress and Solid Cash Runway

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on First Tracks Biotherapeutics Inc, retaining the price target of $30.00.

Emily Bodnar has given his Buy rating due to a combination of factors including the advancement of ANB033 and the company’s solid financial runway. She highlights that First Tracks reaffirmed key milestones, with Phase 1b readouts for ANB033 in celiac disease targeted for 4Q26 and in eosinophilic esophagitis in mid-2027, and notes that the ~$180M pro-forma cash balance should fund operations through both of these catalysts without needing dilutive financing.

She also emphasizes ANB033’s differentiated scientific profile and trial strategy as core to the favorable risk/reward. Preclinical work suggests stronger inhibition of disease-driving T cells versus competing IL-15 or CD122 agents, and the Phase 1b study design spans both prevention of gluten-induced injury and healing of existing mucosal damage, which aligns closely with FDA guidance and could support a compelling efficacy package if the upcoming data are positive.

According to TipRanks, Bodnar is a 4-star analyst with an average return of 10.0% and a 37.88% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Artiva Biotherapeutics, Inc., Agios Pharma, and TG Therapeutics.

In another report released today, Barclays also maintained a Buy rating on the stock with a $40.00 price target.